GlassScriptPhysician profile
Shania W Mcbride
NPI 1790223279
$5,332.92
in general payments reported to CMS, 2019-2025
26 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $756 · 2023: $1,222 · 2024: $1,165 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.43 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $650.26 | 2021-2025 | |
| Sk Life Science, INC. | $637.30 | 2021-2025 | |
| Lundbeck LLC | $362.45 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $358.47 | 2022-2025 | Ajovy, Austedo, Austedo Xr |
| Sumitomo Pharma America, INC. | $269.04 | 2023-2024 | Aptiom |
| Ucb, INC. | $252.59 | 2021-2025 | Briviact, Rystiggo |
| Lilly USA, LLC | $245.90 | 2021-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $244.95 | 2023-2025 | |
| Biogen, INC. | $238.13 | 2021-2025 | Avonex, Skyclarys, Vumerity |
| Eisai INC. | $103.39 | 2024-2025 | |
| Neurelis, INC. | $82.00 | 2023-2024 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $80.23 | 2022 | |
| Axsome Therapeutics, INC. | $72.45 | 2025 | Symbravo |
| Genentech USA, INC. | $72.39 | 2021-2025 | Ocrevus Zunovo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.00 | 2022-2025 | Uplizna |
| Livanova USA, INC. | $62.50 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $58.23 | 2021 | |
| Argenx US, INC. | $29.88 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Ge Healthcare | $22.40 | 2022 | |
| Impel Pharmaceuticals INC. | $19.01 | 2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $18.88 | 2023 | Daybue |
| Mdd US Operations, LLC | $17.75 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.68 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.30 | 2023 | Eprontia |
| Metacel Pharmaceuticals LLC | $9.31 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shania Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.